Neurogene (NGNE) EBITDA (2013 - 2026)
Neurogene's (NGNE) quarterly EBITDA came in at -$33.3 million in Q1 2026, down 28.67% YoY from -$46.8 million in Q1 2025, and down 21.14% on a QoQ basis from -$27.5 million in Q4 2025.
Neurogene (NGNE) EBITDA (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of EBITDA data on file, last reported at -$33.3 million in Q1 2026.
- Quarterly EBITDA fell 28.67% year-over-year to -$33.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$110.8 million (down 23.41% YoY) and the FY2025 annual result came in at -$103.3 million, down 25.09% from the prior year.
- EBITDA fell to -$33.3 million in Q1 2026, from -$27.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$11.7 million in Q4 2022 to a low of -$33.3 million in Q1 2026.
- A 5-year average of -$19.5 million and a median of -$18.8 million in 2024 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA climbed 23.09% — and 2024, when it tumbled 59.84%.
- Tracing NGNE's EBITDA over 5 years: stood at -$11.7 million in 2022, then dropped by 26.24% to -$14.7 million in 2023, then sank by 46.01% to -$21.5 million in 2024, then declined by 27.97% to -$27.5 million in 2025, then dropped by 21.14% to -$33.3 million in 2026.
- The last three EBITDA figures came in at -$33.3 million (Q1 2026), -$27.5 million (Q4 2025), and -$23.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | -36.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.67 Mn |
| Mar 31, 2026 | -33.35 Mn |
| Dec 31, 2025 | -27.53 Mn |
| Sep 30, 2025 | -23.80 Mn |
| Jun 30, 2025 | -26.08 Mn |
| Mar 31, 2025 | -25.92 Mn |
| Dec 31, 2024 | -21.51 Mn |
| Sep 30, 2024 | -22.18 Mn |
| Jun 30, 2024 | -20.13 Mn |
| Mar 31, 2024 | -18.78 Mn |
| Dec 31, 2023 | -14.73 Mn |
| Sep 30, 2023 | -15.22 Mn |
| Jun 30, 2023 | -12.60 Mn |
| Mar 31, 2023 | -13.04 Mn |
| Dec 31, 2022 | -11.67 Mn |
| Sep 30, 2022 | -13.61 Mn |
| Jun 30, 2022 | -15.87 Mn |
| Mar 31, 2022 | -15.37 Mn |
| Dec 31, 2021 | -15.17 Mn |
| Sep 30, 2021 | -15.45 Mn |